Ernest Mui

TL;DR: Proof-of-principle inhibition of the Wnt/β-catenin signalling pathway specifically delays androgen-independent PCa cell cycle progression and proliferation and warrants further investigation as a potential target for therapy for CRPC.

TL;DR: It is shown that elevated levels of PPARG strongly correlate with elevation of FASN in human CaP and that high levels ofPPARG/FASN and PI3K/pAKT pathway activation confer a poor prognosis, and it is suggested that CaP patients could be stratified in terms of PP ARG/ fasN and PTEN levels to identify patients with aggressive CaP who may respond favorably to PPARg/FasN inhibition.

TL;DR: A proteomics and metabolomics characterisation of prostate cancer cells adapted to long-term resistance to AR inhibition and show rewiring of glucose and lipid metabolism, and further identify a signature associated with resistance to Ar inhibition.

TL;DR: In this article, a functional effect of PPARG on AKT serine/threonine kinase 3 (AKT3) was identified, which resulted in a more aggressive disease phenotype.

TL;DR: In this article, the significance of β-catenin activation in prostate cancer progression and treatment resistance was investigated, using clinically relevant murine prostate cancer models, and β-Catenin activations cooperated with Pten loss to drive AR-independent castration-resistant prostate cancer.